The Short Version
These three are often grouped together and are different kinds of thing. Claude Science is a workbench application that scientists run with Anthropic's general models. GPT-Rosalind is a specialised model from OpenAI that approved organisations can call. Isomorphic Labs is an Alphabet drug company that keeps its design engine in house and earns money from partnerships and, eventually, its own medicines. As of November 13, 2026, none of the three has a drug in a registered human trial under its own name.
Side by Side
| Claude Science | GPT-Rosalind | Isomorphic Labs | |
|---|---|---|---|
| Company | Anthropic | OpenAI | Isomorphic Labs, an Alphabet company spun out of Google DeepMind |
| What it is | A research workbench application | A reasoning model for life sciences | A drug discovery company with a proprietary design engine, IsoDDE |
| Launched | Beta on June 30, 2026 | Research preview on April 16, 2026. Left preview September 11, 2026 | Founded 2021. IsoDDE described in February 2026 |
| Who can use it | Paid Claude plans, per launch coverage | Eligible organisations approved through a trusted-access programme | Not offered as a product. Used internally and with partners |
| How it is used | Runs on Linux, macOS or a remote machine, with more than 60 built-in skills and connectors | In ChatGPT Enterprise, Codex and the API, for approved internal research | Isomorphic's own scientists design molecules for its programmes and its partners' targets |
| Named pharma and biotech partners | Bristol Myers Squibb, Novo Nordisk, BigHat Biosciences, Divergence Labs, Enveda, Generate Biomedicines, The Column Group | Novo Nordisk, Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute, UCSF School of Pharmacy | Eli Lilly, Novartis, Johnson & Johnson |
| Published deal values | None | None | Lilly: $45M upfront, up to $1.7B in milestones. Novartis: $37.5M upfront, up to $1.2B. Johnson & Johnson: not disclosed |
| Own drug programmes | Yes, preclinical. Two rare forms of muscular dystrophy, through the acquisition of Mithril Medicine | None announced | Yes, partnered and wholly owned. No candidate named |
| Clinical status | No trial. Anthropic says one could start as soon as late 2028 if candidates hold up | Not applicable | No registered trial found. Company target is a first trial by the end of 2026 |
| Funding specific to this effort | Not disclosed | Not disclosed | $2.1B Series B in May 2026, after $600M in 2025 |
Stated Focus
| Effort | What the company says it is for |
|---|---|
| Claude Science | Bringing separate research tools, databases and analysis into one workspace. Coverage lists genomics, proteomics, structural biology and cheminformatics |
| GPT-Rosalind | Biology, drug discovery and translational medicine: evidence synthesis, hypothesis generation, experiment planning and multi-step research tasks |
| Isomorphic Labs | Designing drugs directly. Its engine covers small molecules, antibodies, peptides and molecular glues, according to its Johnson & Johnson announcement |
Claude Science
Anthropic released Claude Science in beta on June 30, 2026, and at the same event said it would start its own drug discovery programmes for neglected diseases. On October 27 it reported early laboratory and document-review results from six partners and disclosed that it had acquired Mithril Medicine. Anthropic describes the work as early and mostly preclinical. Details and dates are on the Anthropic life sciences partnerships page.
GPT-Rosalind
OpenAI introduced GPT-Rosalind on April 16, 2026, two days after announcing its partnership with Novo Nordisk. Access began with qualified enterprise customers in the United States. Organisations must show legitimate research use, governance controls and restricted access. On September 11 OpenAI said the model was leaving research preview and was available to eligible organisations worldwide. Third-party trackers list API pricing of $5 per million input tokens and $25 per million output tokens from October 5, 2026. OpenAI also released a free life sciences plugin for Codex that connects to more than 50 public databases and works with its standard models.
On benchmarks, OpenAI reported a score of 0.751 on the public BixBench bioinformatics test against 0.732 for GPT-5.4, and said GPT-Rosalind beat GPT-5.4 on 6 of 11 LABBench2 tasks. These are OpenAI's own figures. See OpenAI and Novo Nordisk for the partnership.
Isomorphic Labs
Isomorphic does not sell access to its engine. It is paid through upfront fees, funded research, milestones and royalties from drugmakers, and is building its own pipeline. Its chief executive said in January 2026 that it expects its first clinical trials by the end of 2026, a year later than an earlier target. On November 13, 2026, ClinicalTrials.gov showed no study sponsored by the company. Details are on the Isomorphic Labs funding and clinical trial status page.
How to Think About the Difference
- Tool or drug company. Anthropic and OpenAI mainly sell software that other people's scientists use. Isomorphic designs the molecules itself.
- Who carries the drug risk. With Claude Science and GPT-Rosalind, the customer does. Isomorphic shares it, which is why its deals have milestone payments. See biobucks.
- Overlap is allowed. Novo Nordisk works with both OpenAI and Anthropic. Eli Lilly works with Isomorphic and has a separate lab with Nvidia.
- None is proven in patients. Compounds from other AI drug companies are further along. See AI-designed drugs in clinical trials.
Sources
Anthropic: its October 27, 2026 post, with Pharmaceutical Technology and The Decoder for the launch. OpenAI: The Decoder and AI Catchup, since OpenAI's own page blocked our reader. Isomorphic: its Series B release, its Johnson & Johnson announcement and Reuters via Investing.com. Presenc AI has not tested any of the three. Status as of November 13, 2026.